Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma

Kasper Munch Lauridsen, Marianne Hokland*, Sinan Al-Karradi, Holger Jon Møller, Frede Donskov, Morten Nørgaard Andersen


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


The hemoglobin-haptoglobin scavenger receptor CD163 is present in both a membrane-bound form on monocytes and macrophages (mCD163) and a shed soluble circulating form (sCD163). CD163 is a well-described marker of M2-like tumor-associated macrophages, but in patients with metastatic renal cell carcinoma (mRCC), monocyte mCD163 and serum sCD163 levels have not previously been investigated and associated with patient overall survival (OS). Here, we report mCD163 expression on peripheral blood monocytes, as well as sCD163 serum levels, in samples from 89 patients newly diagnosed with mRCC and 20 healthy controls. We found that in mRCC patients, compared to healthy controls, monocyte mCD163 levels were reduced (P < 0.001) whereas serum sCD163 levels were increased (P = 0.004). Moreover, an inverse correlation between mCD163 and sCD163 levels (P = 0.04) was shown. In survival analyses, intermediary levels of monocyte mCD163 were associated with longest OS, compared to both lower and higher mCD163 levels, which were both associated with worse outcomes (P < 0.01). Further, higher levels of sCD163 at diagnosis were associated with poor OS in both univariate (P < 0.001) and multivariate analysis (HR = 1.28; 95%CI 1.09–1.50, P = 0.002). Importantly, stratification by low vs. high sCD163 was able to separate patients with International Metastatic RCC Database Consortium (IMDC) intermediate risk (IMDCINT) into two subgroups with different OS (P = 0.03): IMDCINT-sCD163LOW showed survival similar to IMDCFAV patients, and IMDCINT-sCD163HIGH showed survival similar to IMDCPOOR patients. Thus, baseline sCD163 is a novel independent biomarker of OS in mRCC, and using sCD163 as an add-on biomarker may improve prognostic value for patients in the heterogenous IMDC intermediate group.

TidsskriftCancer Immunology, Immunotherapy
Udgave nummer2
Sider (fra-til)461-473
StatusUdgivet - feb. 2023

Bibliografisk note

Funding Information:
The study was funded by the Department of Biomedicine, Aarhus University and Department of Clinical Biochemistry, Aarhus University Hospital. KML received a research scholarship from the Danish Cancer Society. FD received a research grant from the Central Denmark Region Health Research Foundation and SAK received a research grant from the Max and Inge Wørzner Memorial Foundation.

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.


Dyk ned i forskningsemnerne om 'Soluble CD163: a novel independent prognostic biomarker in patients with metastatic renal cell carcinoma'. Sammen danner de et unikt fingeraftryk.